Pretreatment prostate specific antigen doubling times

Use in patients before radical prostatectomy

Erik T. Goluboff, Daniel F. Heitjan, Glen M. DeVries, Aaron E. Katz, Mitchell C. Benson, Carl A. Olsson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: We determined whether pre-radical prostatectomy prostate specific antigen (PSA) doubling time could predict pathological stage at radical prostatectomy or PSA failure postoperatively. We also sought to compare PSA doubling times from men with prostate cancer treated with radical prostatectomy to a group treated with radiation therapy. Materials and Methods: Detailed followup was available for 150 patients with clinically localized prostate cancer who underwent radical prostatectomy from January 1993 to August 1995. PSA doubling time was calculated for all patients with 3 or more pre-radical prostatectomy PSA levels using linear regression. We assessed the association between PSA doubling time and PSA failure, pathologic stage at radical prostatectomy, final PSA before treatment and Gleason score. We compared our PSA doubling time values and distribution to a published series of patients with prostate cancer who had undergone radiation therapy. Results: A total of 56 patients had 3 or more PSA values before treatment. Median followup was 17.3 months. PSA doubling time did not correlate with PSA failure, final PSA or Gleason score, but it did with pathological stage at radical prostatectomy (p = 0.0035 for positive margins, p = 0.025 for positive seminal vesicles). Our PSA doubling time and PSA failure rates did not differ from the radiation therapy population with similar followup times. Conclusions: Although studies from the radiation literature have shown PSA doubling time to be useful in predicting PSA failure after treatment for prostate cancer, our results do not confirm this finding. We did find a correlation with pathologic stage at radical prostatectomy, and so longer followup with more patients may confirm this in the future. We also found no significant differences in PSA doubling time between our patients and a group treated with radiation. At least for this parameter, patients with prostate cancer referred for radical prostatectomy and radiation therapy may be similar.

Original languageEnglish (US)
Pages (from-to)1876-1879
Number of pages4
JournalJournal of Urology
Volume158
Issue number5
DOIs
StatePublished - Jan 1 1997

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Radiotherapy
Neoplasm Grading
Radiation
Seminal Vesicles
Treatment Failure

Keywords

  • Prostate
  • Prostate-specific antigen
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Pretreatment prostate specific antigen doubling times : Use in patients before radical prostatectomy. / Goluboff, Erik T.; Heitjan, Daniel F.; DeVries, Glen M.; Katz, Aaron E.; Benson, Mitchell C.; Olsson, Carl A.

In: Journal of Urology, Vol. 158, No. 5, 01.01.1997, p. 1876-1879.

Research output: Contribution to journalArticle

Goluboff, Erik T. ; Heitjan, Daniel F. ; DeVries, Glen M. ; Katz, Aaron E. ; Benson, Mitchell C. ; Olsson, Carl A. / Pretreatment prostate specific antigen doubling times : Use in patients before radical prostatectomy. In: Journal of Urology. 1997 ; Vol. 158, No. 5. pp. 1876-1879.
@article{98c2505e614149f7911033658cd2b0d9,
title = "Pretreatment prostate specific antigen doubling times: Use in patients before radical prostatectomy",
abstract = "Purpose: We determined whether pre-radical prostatectomy prostate specific antigen (PSA) doubling time could predict pathological stage at radical prostatectomy or PSA failure postoperatively. We also sought to compare PSA doubling times from men with prostate cancer treated with radical prostatectomy to a group treated with radiation therapy. Materials and Methods: Detailed followup was available for 150 patients with clinically localized prostate cancer who underwent radical prostatectomy from January 1993 to August 1995. PSA doubling time was calculated for all patients with 3 or more pre-radical prostatectomy PSA levels using linear regression. We assessed the association between PSA doubling time and PSA failure, pathologic stage at radical prostatectomy, final PSA before treatment and Gleason score. We compared our PSA doubling time values and distribution to a published series of patients with prostate cancer who had undergone radiation therapy. Results: A total of 56 patients had 3 or more PSA values before treatment. Median followup was 17.3 months. PSA doubling time did not correlate with PSA failure, final PSA or Gleason score, but it did with pathological stage at radical prostatectomy (p = 0.0035 for positive margins, p = 0.025 for positive seminal vesicles). Our PSA doubling time and PSA failure rates did not differ from the radiation therapy population with similar followup times. Conclusions: Although studies from the radiation literature have shown PSA doubling time to be useful in predicting PSA failure after treatment for prostate cancer, our results do not confirm this finding. We did find a correlation with pathologic stage at radical prostatectomy, and so longer followup with more patients may confirm this in the future. We also found no significant differences in PSA doubling time between our patients and a group treated with radiation. At least for this parameter, patients with prostate cancer referred for radical prostatectomy and radiation therapy may be similar.",
keywords = "Prostate, Prostate-specific antigen, Prostatic neoplasms",
author = "Goluboff, {Erik T.} and Heitjan, {Daniel F.} and DeVries, {Glen M.} and Katz, {Aaron E.} and Benson, {Mitchell C.} and Olsson, {Carl A.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(01)64154-5",
language = "English (US)",
volume = "158",
pages = "1876--1879",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Pretreatment prostate specific antigen doubling times

T2 - Use in patients before radical prostatectomy

AU - Goluboff, Erik T.

AU - Heitjan, Daniel F.

AU - DeVries, Glen M.

AU - Katz, Aaron E.

AU - Benson, Mitchell C.

AU - Olsson, Carl A.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Purpose: We determined whether pre-radical prostatectomy prostate specific antigen (PSA) doubling time could predict pathological stage at radical prostatectomy or PSA failure postoperatively. We also sought to compare PSA doubling times from men with prostate cancer treated with radical prostatectomy to a group treated with radiation therapy. Materials and Methods: Detailed followup was available for 150 patients with clinically localized prostate cancer who underwent radical prostatectomy from January 1993 to August 1995. PSA doubling time was calculated for all patients with 3 or more pre-radical prostatectomy PSA levels using linear regression. We assessed the association between PSA doubling time and PSA failure, pathologic stage at radical prostatectomy, final PSA before treatment and Gleason score. We compared our PSA doubling time values and distribution to a published series of patients with prostate cancer who had undergone radiation therapy. Results: A total of 56 patients had 3 or more PSA values before treatment. Median followup was 17.3 months. PSA doubling time did not correlate with PSA failure, final PSA or Gleason score, but it did with pathological stage at radical prostatectomy (p = 0.0035 for positive margins, p = 0.025 for positive seminal vesicles). Our PSA doubling time and PSA failure rates did not differ from the radiation therapy population with similar followup times. Conclusions: Although studies from the radiation literature have shown PSA doubling time to be useful in predicting PSA failure after treatment for prostate cancer, our results do not confirm this finding. We did find a correlation with pathologic stage at radical prostatectomy, and so longer followup with more patients may confirm this in the future. We also found no significant differences in PSA doubling time between our patients and a group treated with radiation. At least for this parameter, patients with prostate cancer referred for radical prostatectomy and radiation therapy may be similar.

AB - Purpose: We determined whether pre-radical prostatectomy prostate specific antigen (PSA) doubling time could predict pathological stage at radical prostatectomy or PSA failure postoperatively. We also sought to compare PSA doubling times from men with prostate cancer treated with radical prostatectomy to a group treated with radiation therapy. Materials and Methods: Detailed followup was available for 150 patients with clinically localized prostate cancer who underwent radical prostatectomy from January 1993 to August 1995. PSA doubling time was calculated for all patients with 3 or more pre-radical prostatectomy PSA levels using linear regression. We assessed the association between PSA doubling time and PSA failure, pathologic stage at radical prostatectomy, final PSA before treatment and Gleason score. We compared our PSA doubling time values and distribution to a published series of patients with prostate cancer who had undergone radiation therapy. Results: A total of 56 patients had 3 or more PSA values before treatment. Median followup was 17.3 months. PSA doubling time did not correlate with PSA failure, final PSA or Gleason score, but it did with pathological stage at radical prostatectomy (p = 0.0035 for positive margins, p = 0.025 for positive seminal vesicles). Our PSA doubling time and PSA failure rates did not differ from the radiation therapy population with similar followup times. Conclusions: Although studies from the radiation literature have shown PSA doubling time to be useful in predicting PSA failure after treatment for prostate cancer, our results do not confirm this finding. We did find a correlation with pathologic stage at radical prostatectomy, and so longer followup with more patients may confirm this in the future. We also found no significant differences in PSA doubling time between our patients and a group treated with radiation. At least for this parameter, patients with prostate cancer referred for radical prostatectomy and radiation therapy may be similar.

KW - Prostate

KW - Prostate-specific antigen

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0030843379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030843379&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)64154-5

DO - 10.1016/S0022-5347(01)64154-5

M3 - Article

VL - 158

SP - 1876

EP - 1879

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -